Alphabet's DeepMind has developed a new AI that can diagnose eye diseases with 94% accuracy.

DeepMind, the company's artificial intelligence division in the UK, has developed a system that is capable of diagnosing more than 50 different eye diseases with up to 94% accuracy.

The department detailed the project in a study published in the scientific journal Nature-Medical. This system is the result of more than two years of cooperation between DeepMind and Moorfields Eye Hospital. Moorfields Eye Hospital is a UK-based eye care center.

As part of the project, Moorfields was responsible for providing 16,000 anonymous 3D eye scan images for DeepMind. The department uses these documents to train AI systems to learn how to spot specific signs of different diseases. The software uses two different neural networks for analysis: one to process the eye scan image to identify the problem, and the other to translate these findings into diagnostic findings and to determine if there are existing recommended treatment recommendations.

DeepMind tested the diagnostic accuracy of the system with 1000 scans that were not used in training. According to the statement, the software finally achieved a diagnostic accuracy of 94%, during which two positioning errors occurred but no omissions occurred. Although such results do not seem to be entirely satisfactory in their own right, DeepMind points out that such performance has successfully surpassed eight other human ophthalmology medical experts who also participated in the evaluation of scanned images.

The ultimate goal of DeepMind is to successfully shorten the time of treatment when the demand for ophthalmic treatment is increasing. As the population ages and other factors increase, the UK's ophthalmology referral rate increased by 37% between 2007 and 2017. This trend has led to longer patient waiting times and may expose some patients to health risks.

Mustafa Suleyman, co-founder and application AI leader at DeepMind, wrote in a blog post, "The time it takes to analyze these scanned images, plus the amount of scan data that health professionals routinely need to process (in Moorfields alone). At the center, more than 1,000 pictures need to be checked every day, which can lead to long delays between scanning and treatment – ​​which means that patients may not get emergency care. The system we developed is designed to solve this challenge. ”

The department said the software not only diagnoses the disease, but also prioritizes the patient's condition based on their severity. Having said that, DeepMind does not intend to completely replace human doctors. They said the system was implemented as two separate neural networks, and the thinking behind its diagnosis would be available for subsequent validation by medical professionals.

Suleyman writes, “This function is critical because ophthalmology professionals have been playing a key role in determining the type of care and treatment that patients should receive. They carefully review the technology and make recommendations that will make the system fully integrated. The key premise."

DeepMind and Moorfields Eye Hospital plan to begin clinical trials of the system in 2019. As part of the agreement, DeepMind will provide the technology in free form in UK hospitals and community clinics over the next five to 30 years.

DeepMind is also exploring other ways to apply artificial intelligence technology in the medical field. Earlier this year, it worked with the US Department of Veterans Affairs to establish a system designed to better detect acute kidney operations in patients. In addition, another subsidiary, Variily, recently announced a method to use eye scans to determine patients' heart disease.

Monobenzone

Monobenzone can decompose melanin in the skin, and prevent the formation of melanin in the skin, used for the treatment of hyperpigmentation, such as various spots, age spots, melanoma. In addition as intermediates in organic synthesis.

Our company offers variety of products which can meet your multifarious demands.including API Powder.Pharmaceutical Intermediates.Vitamins Powder.Plant Extracts.Food Additive.Peptide Powder and so on We adhere to the management principles of "quality first, customer first and credit-based" since the establishment of the company and always do our best to satisfy potential needs of our customers. Our company is sincerely willing to cooperate with enterprises from all over the world in order to realize a win-win situation since the trend of economic globalization has developed with anirresistible force.

Function:

1.Monobenzone is a compound used as a topical drug for medical depigmentation.

2.The topical application of monobenzone powder in animals decreases the excretion of melanin from melanocytes. The same action is thought to be responsible for the depigmenting effect of the drug in humans.

3.Monobenzone may cause destruction of melanocytes and permanent depigmentation.

4.The histology of the skin after depigmentation with topical monobenzone powder is the same as that seen in vitiligo.

5.The epidermis is normal except for the absence of identifiable melanocytes.

product Photo:

Best Monobenzone,Type 1 3 Collagen,99% Rapamycine Sirolimusa Powder,Hyaluronic Acid Dical

Shaanxi YXchuang Biotechnology Co., Ltd , https://www.peptidenootropic.com